A variety of inherited and acquired human diseases affecting the hematopoietic stem cell (HSC) can potentially be treated with genetic manipulation of the patients HSCs. Potential applications of this technology include therapeutic approaches for common blood disorders (e.g. thalassemia), malignancies (e.g. leukemia) and infectious diseases of the blood cells, such as HIV-1 infection (AIDS). However, with a few exceptions, gene transfer into HSCs of large animal models and humans has thus far proven to be difficult and inefficient. By improving our knowledge of the biological characteristics of the human HSC we will likely gain important insights that will allow us to improve the efficiency of gene transfer in and correction of this elusive target cell. Under this project we have established in vitro and in vivo animal models of human hematopoiesis using hematopoietic progenitors obtained from cord blood, bone marrow or peripheral blood of volunteer donors. These cells are cultured in vitro in a variety of cytokines and growth factors to identify conditions that allow their survival in the absence of differentiation. In addition, the gene expression profile of these cells is studied by microarray analysis. The cells are then subjected to gene transfer using viral vectors that allow for integration of the transferred gene and allowed to differentiate into mature cell lineages in vitro (methylcellulose progenitor colonies) or in vivo using mouse or sheep animal models. The pattern of viral integration sites is studied to verify if trends indicating preferential genomic locations can be identified. These experiments allow comparison of cells with putative hematopoietic stem cell activity isolated from various sources (e.g. cord blood vs. bone marrow vs. peripheral blood) and testing of vectors and gene transfer conditions that efficiently target these cells. We have also developed an in vitro model of retroviral insertional oncogenesis that can be applied to murine and human hematopoietic stem cells to study the effects of genetic manipulation with retroviral vectors. These experiments will also allow to test the efficacy of safety modification of gene transfer vector that can be transferred to future human trials. We are employing strategies for precise editing of genome information to be used as correction tools for genetic diseases. These strategies will be applied to HSC obtained directly from mice and humans or through reprogramming technologies to test their safety and efficacy.

Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2011
Total Cost
$636,521
Indirect Cost
Name
National Human Genome Research Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Simon, Karen L; Anderson, Stacie M; Garabedian, Elizabeth K et al. (2014) Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol 133:896-9.e4
Wilson, Michael R; Naccache, Samia N; Samayoa, Erik et al. (2014) Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med 370:2408-17
Sadhukhan, Sanjoy; Sarkar, Koustav; Taylor, Matthew et al. (2014) Nuclear role of WASp in gene transcription is uncoupled from its ARP2/3-dependent cytoplasmic role in actin polymerization. J Immunol 193:150-60
Sood, Raman; Carrington, Blake; Bishop, Kevin et al. (2013) Efficient methods for targeted mutagenesis in zebrafish using zinc-finger nucleases: data from targeting of nine genes using CompoZr or CoDA ZFNs. PLoS One 8:e57239
Oh, Julia; Freeman, Alexandra F; NISC Comparative Sequencing Program et al. (2013) The altered landscape of the human skin microbiome in patients with primary immunodeficiencies. Genome Res 23:2103-14
Prislovsky, Amanda; Zeng, Xueying; Sokolic, Robert A et al. (2013) Platelets from WAS patients show an increased susceptibility to ex vivo phagocytosis. Platelets 24:288-96
Barber, John S; Yokomizo, Lauren K; Sheikh, Virginia et al. (2013) Peptide library-based evaluation of T-cell receptor breadth detects defects in global and regulatory activation in human immunologic diseases. Proc Natl Acad Sci U S A 110:8164-9
Lawrence, Monica G; Barber, John S; Sokolic, Robert A et al. (2013) Elevated IgE and atopy in patients treated for early-onset ADA-SCID. J Allergy Clin Immunol 132:1444-6
Shimizu, Masaki; Kanegane, Hirokazu; Wada, Taizo et al. (2013) Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. J Allergy Clin Immunol 131:587-90.e1-3
Horino, Satoshi; Uchiyama, Toru; So, Takanori et al. (2013) Gene Therapy Model of X-linked Severe Combined Immunodeficiency Using a Modified Foamy Virus Vector. PLoS One 8:e71594

Showing the most recent 10 out of 22 publications